These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 26016221)

  • 1. [Raynaud's phenomenon - first sign of malignancy: case report].
    Sutić A; Gračanin G; Morović-Vergles J
    Acta Med Croatica; 2014 Jun; 68(3):295-8. PubMed ID: 26016221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of endothelin-1 and selected cytokines in the pathogenesis of Raynaud's phenomenon associated with systemic connective tissue diseases.
    Rychlik-Golema W; Mastej K; Adamiec R
    Int Angiol; 2006 Jun; 25(2):221-7. PubMed ID: 16763543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Etiological profile of secondary Raynaud's phenomenon in an internal medicine department. About 121 patients].
    Ben Salem T; Tougorti M; Bziouech S; Lamloum M; Khanfir M; Ben Ghorbel I; Houman MH
    J Med Vasc; 2018 Feb; 43(1):29-35. PubMed ID: 29425538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-cardiolipin antibodies, Raynaud's phenomenon with digital ischemia, and non small cell carcinoma of the lung.
    Vaidya S; Logan JW
    Scand J Rheumatol; 2001; 30(3):172-4. PubMed ID: 11469530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Raynaud's phenomenon.
    Lally EV
    Curr Opin Rheumatol; 1992 Dec; 4(6):825-36. PubMed ID: 1457277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies.
    Kallenberg CG; Pastoor GW; Wouda AA; The TH
    Ann Rheum Dis; 1982 Aug; 41(4):382-7. PubMed ID: 7051989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Prognostic factors in Raynaud's phenomenon: usefulness of antinuclear antibodies and of periungual capillaroscopy].
    Passiu G; Sebastiani GD; Galeazzi M; Tuveri MA; Nicosia PM; Boirivant R
    Medicina (Firenze); 1990; 10(4):405-7. PubMed ID: 2099984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical utility of antinuclear antibody tests in children.
    McGhee JL; Kickingbird LM; Jarvis JN
    BMC Pediatr; 2004 Jul; 4():13. PubMed ID: 15245579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Raynaud's phenomenon.
    Devgire V; Hughes M
    Br J Hosp Med (Lond); 2019 Nov; 80(11):658-664. PubMed ID: 31707892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.
    Moinzadeh P; Nihtyanova SI; Howell K; Ong VH; Denton CP
    Clin Rev Allergy Immunol; 2012 Dec; 43(3):249-55. PubMed ID: 22711501
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nailfold capillaroscopic findings in primary Sjögren's syndrome with and without Raynaud's phenomenon and/or positive anti-SSA/Ro and anti-SSB/La antibodies.
    Corominas H; Ortiz-Santamaría V; Castellví I; Moreno M; Morlà R; Clavaguera T; Erra A; Martínez-Pardo S; Ordóñez S; Santo P; Reyner P; González MJ; Codina O; Gelman MS; Juanola-Roura X; Olivé A; Torrente-Segarra V;
    Rheumatol Int; 2016 Mar; 36(3):365-9. PubMed ID: 26597492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
    Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
    Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Raynaud's phenomena: diagnostic and treatment study].
    Priollet P
    Rev Prat; 1998 Oct; 48(15):1659-64. PubMed ID: 9814067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occlusive digital artery disease in patients with Raynaud's phenomenon.
    Zweifler AJ; Trinkaus P
    Am J Med; 1984 Dec; 77(6):995-1001. PubMed ID: 6334442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raynaud's phenomenon and positive antinuclear antibodies in a malignancy.
    Tolosa-Vilella C; Ordi-Ros J; Vilardell-Tarres M; Selva-O'Callaghan A; Jordana-Comajuncosa R
    Ann Rheum Dis; 1990 Nov; 49(11):935-6. PubMed ID: 2256742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Raynaud's phenomenon in mixed connective tissue disease.
    Grader-Beck T; Wigley FM
    Rheum Dis Clin North Am; 2005 Aug; 31(3):465-81, vi. PubMed ID: 16084319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Raynaud's phenomenon, disease or syndrome?].
    Fiessinger JN
    Rev Prat; 2011 Sep; 61(7):899-903. PubMed ID: 22039719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How to classify Raynaud's phenomenon. Long-term follow-up study of 73 cases.
    Priollet P; Vayssairat M; Housset E
    Am J Med; 1987 Sep; 83(3):494-8. PubMed ID: 3661586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Raynaud's phenomenon and antiphospholipid antibodies in systemic lupus erythematosus: is there an association?
    Caccavo D; Del Porto F; Garzia P; Mitterhofer AP; Galluzzo S; Rigon A; Vadacca M; Navajas MF; Amoroso A; Afeltra A
    Ann Rheum Dis; 2003 Oct; 62(10):1003-5. PubMed ID: 12972482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.